Mizuho Bullish on Horizon Pharma (HZNP) Into Today's Investor Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
November 10, 2015 6:57 AM ESTHorizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More
Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook
November 6, 2015 7:01 AM ESTHorizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.70, $0.30 better than the analyst estimate of $0.40. Revenue for the quarter came in at $292.7 million versus the consensus estimate of $185.7 million.
Horizon Pharma sees FY2015 revenue of $750-760 million, versus prior guidance of $660-680 million and the... More



